Exelixis reported $124.89M in Pre-Tax Profit for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Pre Tax Profit Change
Acadia Pharmaceuticals ACAD:US $ -43.4M 23.03M
Acceleron Pharma XLRN:US $ -63.51M 0.05M
Agios Pharmaceuticals AGIO:US $ -82.79M 8.09M
Akebia Therapeutics AKBA:US $ -83.04M 13.46M
Bayer BAYN:GR € 1537M 1825M
Bluebird Bio BLUE:US $ -231.42M 25.67M
Cytokinetics CYTK:US $ -61.55M 14.45M
Dicerna Pharmaceuticals DRNA:US $ -40.27M 10.3M
Eisai 4523:JP Y 55783M 61588M
Eli Lilly And LLY:US $ 1988.6M 80.6M
Esperion Therapeutics ESPR:US $ -43668000 47.27M
Exelixis EXEL:US $ 124.89M 126.9M
Genmab GEN:DC DK 422M 1002M
Immunogen IMGN:US $ -30.74M 3.31M
IONIS PHARMACEUT IONS:US $ -81M 8.74M
Macrogenics MGNX:US $ -39.94M 11.34M
Moderna Inc MRNA:US 3.06B 1.8B
Nektar Therapeutics NKTR:US $ -125.16M 3.89M
Neurocrine Biosciences NBIX:US $ 57.5M 30.3M
Novartis NOVN:VX SF 4424M 620M
Ultragenyx Pharmaceutical RARE:US $ -121.96M 13.8M
Xencor XNCR:US $ 52.25M 54.74M
YTE INCY:US $ 199.6M 31.06M